Company: ADPT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001193125-25-103752
Chunk: 11

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 11
---
 promotional efforts in MCL in the fourth quarter of 2024. |

| • |     | We obtained a new Medicare Clinical Laboratory Fee Schedule rate of $2,007 per test for clonoSEQ and MolDX updated the clonoSEQ episode pricing to $8,029 for all covered indications. This represents a 17% increase from the previous episode price and the previous implied per test rate under the episode structure. |

| • |     | We have integrated the clonoSEQ clinical diagnostic test via the Epic System Corporation’s comprehensive electronic medical record system into the records systems of 18 accounts through 2024 to enable easier test ordering. |

| • |     | Our clonoSEQ assay was being used in more than 170 active trials being conducted by over 40 biopharmaceutical partners, including more than 85 trials where MRD is a clinical endpoint (14 of which use MRD as a primary endpoint). |

IM Business Highlights

| • |     | In oncology, we are jointly pursuing with Genentech the development and delivery of the highest impact antigen-directed TCR based cell therapy for the treatment of patients with different solid tumor types. In 2024, we made significant progress to improve turnaround times and reduce costs, which we believe will enhance the profile of potential cell therapy product(s). |

| • |     | In autoimmunity, we narrowed our focus to select T-cell mediated indications with high unmet clinical and commercial need, such as multiple sclerosis (MS) and type 1 diabetes, among others. In these indications we successfully identified a subset of autoreactive or problem T cell receptors that are likely causing disease. Our therapeutic strategy is to eliminate or block the activation of these problem |

6

| T cells and directly stop them from attacking healthy tissue. To date, we completed several antibody mouse immunization campaigns and successfully selected and functionally tested a subset of antibodies to a number of disease-causing targets in prioritized indications. Based on the data we collected, we nominated a lead indication and are focusing on the preclinical development of antibody therapeutic candidates in this first indication. |

Selected Operational Highlights Environmental Stewardship We are committed to operating in an environmentally responsible and efficient manner to minimize adverse impacts on the environment and support long-term value creation for our stakeholders. In 2024, Adaptive voluntarily submitted to the Carbon Disclosure Project (“CDP”), a global environmental impact non-profitthat provides a platform for companies and cities to report information on their climate, water and deforestation impacts, and we received